Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lothar Bergmann

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
European Journal of Haematology|July 14, 2011
Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemiaKai Uwe Chow, Soo-Zin Kim, Nils von Neuhoff, et al.
BMC Cancer|December 12, 2012
GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centersSylvia Hartmann, Claudio Agostinelli, Jürgen Diener, et al.
Experimental Hematology|September 13, 2002
Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemiaJochen Greiner, Mark Ringhoffer, Masanori Taniguchi, et al.
Investigational New Drugs|April 13, 2011
Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group)Beate Schultheis, Dirk Strumberg, Lothar Bergmann, et al.
European Urology|September 10, 2013
Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancerAndres Jan Schrader, Sandra Seseke, Christian Keil, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2015
Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studiesLaurence Albiges, Ulrich Kube, Jean-Christophe Eymard, et al.
Leukemia & Lymphoma|July 7, 2007
The tyrosine kinase inhibitor AMN107 (Nilotinib) exhibits off-target effects in lymphoblastic cell linesKai Uwe Chow, Daniel Nowak, Bettina Trepohl, et al.
Oncology Research and Treatment|June 17, 2020
A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer SocietyLothar Bergmann, Viktor Grünwald, Luise Maute, et al.
Oncology Research and Treatment|January 21, 2019
Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO StudyPeter J Goebell, Edwin Hermann, Ulrich Kube, et al.
The Oncologist|December 2, 2015
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human UseIordanis Gravanis, Kyriaki Tzogani, Paula van Hennik, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
European Journal of Haematology|July 14, 2011
Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemiaKai Uwe Chow, Soo-Zin Kim, Nils von Neuhoff, et al.
BMC Cancer|December 12, 2012
GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centersSylvia Hartmann, Claudio Agostinelli, Jürgen Diener, et al.
Experimental Hematology|September 13, 2002
Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemiaJochen Greiner, Mark Ringhoffer, Masanori Taniguchi, et al.
Investigational New Drugs|April 13, 2011
Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group)Beate Schultheis, Dirk Strumberg, Lothar Bergmann, et al.
European Urology|September 10, 2013
Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancerAndres Jan Schrader, Sandra Seseke, Christian Keil, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2015
Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studiesLaurence Albiges, Ulrich Kube, Jean-Christophe Eymard, et al.
Leukemia & Lymphoma|July 7, 2007
The tyrosine kinase inhibitor AMN107 (Nilotinib) exhibits off-target effects in lymphoblastic cell linesKai Uwe Chow, Daniel Nowak, Bettina Trepohl, et al.
Oncology Research and Treatment|June 17, 2020
A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer SocietyLothar Bergmann, Viktor Grünwald, Luise Maute, et al.
Oncology Research and Treatment|January 21, 2019
Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO StudyPeter J Goebell, Edwin Hermann, Ulrich Kube, et al.
The Oncologist|December 2, 2015
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human UseIordanis Gravanis, Kyriaki Tzogani, Paula van Hennik, et al.
Pageof 5